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A B S T R A C T
We report a case of a 31-year-old otherwise healthy female with pulmonary cryptococcoma along with cryp-
tococcal meningitis due to Cryptococcus gattii molecular type VGI, in Greece. Combined antifungal treatment and
surgical excision of pulmonary cryptococcoma yielded a good response.
1. Introduction
Cryptococcosis is a life-threatening fungal disease aﬀecting both
immunosuppressed and immunocompetent hosts. Etiological agents
known to cause infection in humans are the two species complexes
Cryptococcus neoformans and Cryptococcus gattii. Although in the past
they were classiﬁed as two varieties of C. neoformans species, further
studies conﬁrmed that C. neoformans and C. gattii actually diﬀer in
geographical distribution, genetic characteristics, and virulence. C.
gattii species complex contains ﬁve molecular types AFLP4/VGI,
AFLP6/VGII, AFLP10/VGIV, AFLP5/VGIII and AFLP7/VGIV [1,2].
Primary infection is thought to be caused by the inhalation of ba-
sidiospores or small-sized blastospores. After lung penetration, crypto-
coccal yeasts can enter the bloodstream and cross blood-brain-barrier
causing central nervous system infection. Interestingly Cryptococcus
gattii is more likely to cause lung or brain cryptococcomas, while
Cryptococcus neoformans causes more disseminated disease [3]. Cryp-
tococcus neoformans species complex has a worldwide distribution af-
fecting predominantly immunocompromised hosts. Host risk factors for
infection include underlying HIV infection, solid organ transplantation,
idiopathic CD4+ lymphopenia, corticosteroid or immunosuppressive
drugs use and other immunosuppressive states such as diabetes, auto-
immune diseases [3,4]. In contrast, C. gattii has been found mainly in
tropical and subtropical areas and molecular types VGI and VGII have
been shown to be able to infect otherwise healthy immunocompetent
individuals. Recent data show a change in ecological distribution of C.
gattii species complex to temperate non-endemic areas worldwide, in-
cluding Europe and Mediterranean basin [5–8]. In Greece, previous
reports with clinical cases of C. gattii infection were reported only in
immunocompromised patients [9,10]. Here we present a case of C. gattii
VGI infection in an immunocompetent host in our country.
2. Case
A 31-year-old woman from a rural area of southwestern
Peloponnese in Greece was transferred to our hospital, a tertiary care
hospital facility, with a two-week history of mild headache and low-
grade fever. Three days prior admission she experienced vomiting,
fever up to 38.5 °C, and mental confusion. She had no prior medical
history and had never been abroad.
On examination (day 0) she was afebrile, hemodynamically stable,
mildly confused with Glasgow coma scale: 13/15 and no focal neuro-
logic deﬁcits. Brain computed tomography (CT) and magnetic re-
sonance imaging (MRI) depicted multiple small nodular lesions at
peripheral sites of cerebellar hemispheres, small focal lesions in the
posterior limp of internal capsule and in the left hypothalamic nucleus.
https://doi.org/10.1016/j.mmcr.2019.12.002
Received 9 October 2019; Received in revised form 3 November 2019; Accepted 2 December 2019
∗ Corresponding author. Division of Infectious Diseases, Department of Internal Medicine, Patras University Hospital, 26504, Patras, Greece.
E-mail address: alekkou@yahoo.gr (A. Lekkou).
Medical Mycology Case Reports 27 (2020) 1–3
Available online 03 December 2019
2211-7539/ © 2019 The Authors. Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology. This is an open access article 
under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
After the administration of paramagnetic drug, meningeal enhancement
was detected (Fig. 1).
Initial cerebrospinal ﬂuid (CSF) analysis showed lymphocytic
pleocytosis (white cell count: 670 cells/mmᶟ, 96% lymphocytes, 3%
neutrophils), protein of 82.6 mg/dl and glucose of 36 mg/dl (blood
glucose 90 mg/dl). CSF opening pressure was 36 cm H₂O. Latex ag-
glutination test for Cryptococcus was positive while CSF cryptococcal
antigen (CrAg) titer was 1:20. After 48 h incubation at 37 °C,
Cryptococcus grew in the CSF culture. Cryptococcus gattii was identiﬁed
by matrix-assisted laser desorption/ionization time of ﬂight mass
spectrometry (MALDI-TOF Vitek MS Biomerieux, database IVD).
Antifungal susceptibility test was performed by E-test. The MICs of the
antifungals were: 0.25 μg/ml for amphotericin B, 0.016 μg/ml for ﬂu-
cytosine, 4 μg/ml for ﬂuconazole and 0.125 μg/ml for voriconazole.
The fungal isolate was sent to the Medical Mycology Laboratory at
Università degli Studi di Milano for further molecular characterization,
where it was identiﬁed as molecular type VGI, mating type αB by
multiplex PCR [11] and sequence type ST197 by standard multi-locus
sequence type (MLST) analysis [12]. Chest x-ray (day 0) and CT (day
+4) revealed a well-deﬁned, non-enhancing, of low-density mass lesion
in the left lower lobe.
The patient received combined regimen with liposomal amphoter-
icin B (LAmB) 4 mg/kg/d and ﬂucytosine 100 mg/kg/d in four divided
doses IV. Two days after starting treatment she complained of sudden
onset of acute retrosternal chest pain and ECG showed T wave de-
pression in V1 – V3 and ﬂattened T waves in V4 – V6, but no cardiac
enzymes elevation was observed, as ﬂucytosine adverse reaction.
Treatment was changed to LAmB and ﬂuconazole 800 mg/d IV and she
improved steadily through ﬁrst 3 weeks. The patient underwent
bronchoscopy (day +14) and bronchoalveolar lavage did not evidence
acid-fast bacilli, fungi or bacteria.
On week 4, patient's symptoms relapsed as well as MRI ﬁndings,
showing increased enhancement of the lesions in cerebellar hemi-
spheres and basal ganglia bilaterally. C. gattii was isolated from CSF. We
continued treatment with daily ﬂuconazole 800 mg, increased dose of
LAmB (5 mg/kg/d IV) and repeated lumbar punctures demonstrated
persistent high opening pressure (42 cm H₂O) which improved with
large volume drainage.
A complete microbiological and immunological evaluation was
performed, detecting no any underlying immunosuppression state.
Initial low CD4+ levels (332 cells/μl) were restored (1185 cells/μl)
after 6 weeks of treatment. HIV serology tests and HTLV-I/II antibody
were negative.
On week 9, CSF analysis conﬁrmed sterility and CrAg titre 1:10,
concurrently with improvement of clinical presentation. Follow-up
chest CT revealed unchanged lung lesion and the patient was submitted
to an exploratory thoracotomy, which depicted a solid mass adhered to
the parietal pleura involving the left inferior lobe. An inferior lo-
bectomy was undertaken and the post-operative outcome was good
(Fig. 2). Histology demonstrated foamy histiocyte inﬁltration, necrotic
areas surrounded by granulomas with epitheliod histiocytes and giant
cells besides the presence of numerous birefringent structures and no
evidence of malignancy. Grocott methenamine silver and Mayer's mu-
cicarmine stainings were positive and diagnosed the structure as
Cryptococcus spp. (Fig. 3).
The patient was transitioned to oral ﬂuconazole 800 mg daily but,
on week 12, she came back with left VI nerve palsy. Brain MRI ﬁndings
showed disease exacerbation and lumbar puncture revealed a CSF
opening pressure 38 cm H₂O, pleocytosis (107 cells/μl, lymphocytes
68%), normal glucose and protein concentrations and CSF CrAg titre
1:10. Treatment with LAmB 4 mg/kg/d and voriconazole (6 mg/kg/bid
initially and then 4 mg/kg/bid) was initiated with frequent CSF drai-
nages. CSF culture was negative but, on week 13, further deterioration
occurred with enhancement of existing hyper-intensities on repeat MRI
imaging. She was commenced on high-dose steroids for immune re-
constitution inﬂammatory syndrome (IRIS) 0.5 mg/kg twice daily for
two days followed by 0.5 mg/kg/d oral prednisolone for four weeks,
which was weaned over further ﬁve months. After clinical improve-
ment, she was discharged on salvage consolidation and suppressive
therapy with voriconazole 200 mg/bid per os and 18 months later she is
in a good clinical condition without neurological deﬁcits.
3. Discussion
C. gattii was known to be endemic in subtropical and tropical re-
gions but since 1999, when Vancouver Island outbreak occurred, in-
creasing numbers of cases have been reported in the Paciﬁc Northwest
of the United States and in other temperate regions worldwide
[5,13,14]. A European survey carried out during 1997–1999 reported
C. gattii serotype B isolates from Germany, France and Greece, and one
C. gattii serotype C in an HIV patient in the UK [15]. Subsequently, a
review on the global distribution of molecular types reported cases in
Portugal, Spain, Italy and the Netherlands all of VGI molecular type, as
well as few VGII isolates in Greece, Switzerland, the Netherlands and
Denmark and one VGIII isolate in Greece. The three cases from Greece
were all in immunocompromised patients, two HIV/AIDS patients and
one patient with systematic lupus erythematosus receiving im-
munosuppressive therapy [9,10].
C. gattii species complex isolates were also recovered in auto-
chthonous Mediterranean trees. Recently, investigators concluded that
the probability of presence for C. gattii drastically dropped when ex-
posed to environments with a minimum temperature in winter of few
degrees below 0 °C whereas the presence of the pathogen was higher in
Fig. 1. Magnetic resonance imaging: Multiple cryptococcoma lesions in the
cerebellar hemisperes, the internal capsule and the left hypothalamic nucleus
(arrows). After the administration of paramagnetic drug, meningeal enhance-
ment was detected.
Fig. 2. Pulmonary cryptococcoma: A well circumscribed mass of the left in-
ferior lung lobe.
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the areas where rainfall was scarce during summer. On the basis of
these ﬁndings Mediterranean climate is potentially optimal for C. gattii
colonization [7].
We report a case in an immunocompetent female in Greece with
combined lung cryptococcoma and central nervous system disease due
to C. gattii. She was infected by a Cryptococcus gattii strain, molecular
type VGI, mating type αB, and belonging to genotype ST197, which is
one of the autochthonous VGI genotypes forming a larger cluster pre-
sent in the Mediterranean area [5,10]. Since the patient had never
travelled abroad, the infection was acquired in Greece. Initial low
CD4+ levels were a manifestation of relative immunosuppression pos-
sibly induced by the cryptococcal capsule and restored after treatment
[16].
Recommendations for the treatment of C. gattii central nervous
system infection are the same as for C. neoformans. Amphotericin B plus
ﬂucytosine are proposed as ﬁrst-line treatment but in our case, because
of ﬂucytosine adverse reaction, treatment switched to liposomal am-
photericin and ﬂuconazole regimen. After relapse and taking into ac-
count the new therapeutic options of the disease, salvage consolidation
therapy with voriconazole was initiated [16].
Currently, surgery is not routinely recommended for lung crypto-
coccomas, except in case of mass-lesion eﬀects or failure of treatment
after four weeks [17]. A few studies show favorable outcome in cases
with combined pulmonary and CNS cryptococcosis, after surgical re-
section of lung cryptococcomas [18,19].
In our case, we assumed that the presence of pulmonary crypto-
coccoma was associated with recurrent relapses and treatment failure.
Surgical removal of lung lesion appeared to favor treatment response.
After an initial clinically favorable response, the delayed worsening of
our patient was due to IRIS, as occurred in 11% of patients in a large
case series from Australia [3]. Systemic corticosteroid use is a poten-
tially life-saving intervention to be considered for the management of
IRIS in cryptococcal meningitis, however, precision of dosing and
duration of therapy are uncertainties that require further study [16].
Global climatic changes expect to play a major role in the dis-
tribution of C. gattii species complex worldwide. As cryptococcosis is a
life-threatening disease and C. gattii is a pathogen with increasing in-
cidence in Europe and Mediterranean area, more research need to be
done for early detection of outbreaks.
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